Company Snapshot
CVRx, Inc. investment report
Start with CVRX at a glance, then work through valuation, price history, fundamentals, management, competitors, and analyst expectations.
CVRx, Inc.
NASDAQ:CVRXMedical - Devices
+$0.11 today
- Market cap
- $69.79M
- Beta
- 0.77
- P/E (TTM)
- -2.5
- EPS (TTM)
- -$2.00
Volume 0.37M
Average 0.30M
Intrinsic Value
CVRX Intrinsic Value
Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.
CVRx, Inc.
NASDAQ:CVRX
Intrinsic Alpha fair value
Locked
Current Price
$2.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Monitor CVRX
Get notified when the price moves into your range
Use alerts to turn the valuation into an action plan instead of checking the stock manually.
Price alerts
Get notified when CVRX drops below your target
Current price baseline
$2.63
Current price $2.63
Sign in to activate price alerts.
Price History
How has CVRX traded over time?
Review how the market has priced CVRx, Inc. over time, alongside earnings and dividend events, before deciding whether today’s price is unusual.
Price history
Dividend-adjusted closing price
Period change
-70.11%
Period high
$9.99
Period low
$2.37
Latest
$2.63
Investment Notes
Capture the investment case
Write down the key idea, risks, and what would change your mind before testing the thesis against the fundamentals below.
My notes
Journal entries for CVRX
Sign in to keep notes
Keep your research and decisions in your personal journal.
Fundamental Analysis
Test company quality against your thesis
Work through profitability, revenue mix, financial position, cash generation, compounding numbers, and growth to see whether the business supports the investment case.
Earnings Quality
Follow revenue through to net income
Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.
CVRX Earnings Waterfall · TTM
NASDAQ:CVRX · Revenue to Net Income
Key Ratios
Analysis
$59.1M of revenue converted into -$52.7M of net income for the selected period. Gross margin is 85.5% and net margin is -89.8%, showing how much revenue survives after costs and taxes. EPS is $-2.02, tying the income statement back to per-share earnings.
Revenue Mix
See which products and regions drive the business
Growth is easier to trust when you know where it comes from. Check whether one segment or region carries the company and how the mix is shifting.
Revenue by segment
Where CVRX earns its revenue, as reported in company filings
This company does not report revenue segments.
Financial Position
Check what supports the company underneath the income statement
The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $72.3M |
| Receivables | $9.1M |
| Inventory | $12.4M |
| Other Current | $2.9M |
| Total Current Assets | $96.8M |
| PP&E (Net) | $3.0M |
| Other Non-current | $26.0K |
| Total Non-current Assets | $3.0M |
| Total Assets | $99.7M |
Analysis
Selected assets total $99.7M for Latest. The largest visible component is Cash & Equivalents at $72.3M, about 72.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Cash Generation
Test whether profit turns into cash
Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.
Free Cash Flow
Net Income to FCF bridge
FY2025
Analysis
FY2025 free cash flow is -$40.8M. FCF conversion is 76.4% of net income. Operating cash flow was -$40.2M, with capex of -$580.0K. The largest bridge item is Stock-Based Comp at $11.1M.
Quality Snapshot
Check the numbers that compound value
Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.
Big Five Numbers
CAGR by period · ROIC shows average
| Metric | 10yr | 5yr | 3yr | 1yr |
|---|---|---|---|---|
EPS | Not available | Not available | Not available | Not available |
Revenue | Not available | Not available | +36.1% | +10.4% |
Equity | Not available | Not available | -34.3% | -52.1% |
Cash | Not available | Not available | -10.7% | -28.5% |
ROIC | Not available | -39.7% | -48.2% | -56.0% |
Analysis
In the latest year, Revenue was strongest at +10.4%, while ROIC was weakest at -56.0%. The three-year average ROIC was -48.2%, a measure of how efficiently the company earned that growth.
Growth Profile
Compare historical growth with forward expectations
Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +36.1% | +16.8% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +36.1% over three years. Forward estimates point to Revenue at +16.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Management
Judge how CVRx, Inc. allocates capital
Review returns on capital, owner payouts, dividend durability, insider activity, and the leadership responsible for these decisions.
Capital Efficiency
Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.
Return Metrics
ROE, ROIC & ROA over time
ROE
-135.6%
avg -47.4%
ROIC
-56.0%
avg -38.4%
ROA
-50.9%
avg -37.9%
Analysis
ROA is currently the strongest return metric at -50.9% versus its period average of -37.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Dividend Record
A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.
Dividends
Dividend history, growth & yield
Yield
0.00%
Annual Div/Share
$0.00
Payout Ratio
0.0%
Frequency
—
Shareholder Yield
0.00%
Next Ex-Date
Not announced
Next Payment
—
Analysis
The current indicated dividend yield is 0.00%. The payout ratio is 0.0%, so compare payout growth against earnings coverage.
Owner Returns
Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.
Shareholder Returns
Dividend, buyback & debt paydown yields
Dividend Yield (TTM)
0.00%
Buyback Yield (TTM)
0.06%
Debt Paydown (TTM)
0.00%
Total Yield (TTM)
0.06%
Analysis
Total TTM shareholder yield is 0.06% including 0.00% from debt paydown. The largest current contributor is buybacks at 0.06%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.
Insider Activity
Insider transactions add context to ownership incentives and can reveal when leadership behavior diverges from the public investment case.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$376,809.04
Sells
11
$444,645.54
Net Transaction Value
−$67,836.50
Net selling
Most Active
JOHNSON & JOHNSON
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 13, 26Aug 13, 2026 | Binkowski Brent Direct | Buy | $76.4K$76,432.18 |
| Aug 12, 26Aug 12, 2026 | Binkowski Brent Direct | Sell | $3.3K$3,338.21 |
| Mar 2, 26Mar 2, 2026 | OASHEIM JARED Direct | Sell | $13.8K$13,781.44 |
| Mar 2, 26Mar 2, 2026 | Adamson Philip B. Direct | Sell | $10K$9,973.21 |
| Mar 2, 26Mar 2, 2026 | John Robert Allen Direct | Sell | $31.3K$31,325.51 |
| Mar 2, 26Mar 2, 2026 | VERRASTRO PAUL Direct | Sell | $10.1K$10,146.30 |
| Mar 2, 26Mar 2, 2026 | Hykes Kevin Direct | Sell | $61.3K$61,348.66 |
| Feb 20, 26Feb 20, 2026 | Jain Mudit K. Indirect | Buy | $297.6K$297,591.84 |
| Feb 18, 26Feb 18, 2026 | Jain Mudit K. Direct | Buy | $2.8K$2,785.02 |
| Nov 26, 25Nov 26, 2025 | JOHNSON & JOHNSON Indirect | Sell | $63.6K$63,560.11 |
1–10 of 14
Summary
Insiders reported 3 buys worth $376,809.04 and 11 sells worth $444,645.54 over the last 12 months. That adds up to net selling of $67,836.50. JOHNSON & JOHNSON was the most active insider with 5 transactions.
Leadership
Leadership context helps you judge who is responsible for strategy, capital allocation, and execution.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Kevin Hykes | President, Chief Executive Officer & Director | USDÂ 2.64M | 60 | 284.24K | 1.07% |
Philip Adamson | Chief Medical Officer | USD 1.1M | 65 | — | — |
Robert Allen John | Chief Revenue Officer | USDÂ 1.05M | 52 | 86.04K | 0.32% |
Paul Verrastro | Chief Marketing & Strategy Officer | USDÂ 598.97K | 63 | 60.55K | 0.23% |
Jared Oasheim | Chief Financial Officer | USDÂ 517.27K | 43 | 96.70K | 0.36% |
Bonnie Handke | Senior Vice President of Patient Access, Reimbursement, & Healthcare Economics | — | — | — | — |
Brent Binkowski | Chief Operating Officer | — | 57 | 56.51K | 0.21% |
Gregory Morrison | Chief Human Resources Officer | — | 62 | 0 | <0.01% |
Compensation is shown in the reported currency; data updated Aug 29, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 13, 2026.
Alternatives to CVRX
Compare CVRx, Inc. with similar companies
A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.
Competitors
Peer companies in the same sector
Analysts
What Wall Street expects from CVRX
Compare consensus price targets and ratings with your own valuation to understand how much optimism the market is already pricing in.
Analyst Targets
See where analysts expect CVRX to trade next
Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.
Wall Street price targets
1-year price history with analyst consensus target
Unlock analyst target range
Sign in free to see low, average, high targets and implied upside for CVRX.
Analyst Ratings
How analysts rate CVRX today
See the buy, hold, and sell split behind the consensus and whether recent rating changes lean toward upgrades or downgrades.
Analyst ratings
Buy, hold, and sell recommendations and recent rating changes
No analyst ratings available.
Company Overview
Understand how CVRx, Inc. makes money
Ground the financial evidence in the company profile, business description, and key facts.
Key Information
Stock Analysis
Turn the CVRX report into your next decision
Record your conclusion, evidence, and concerns in a structured analysis workspace.
Investment analysis
Turn CVRX research into a decision
Work through Know the Business, Test the Moat, Management, and Intrinsic Value in one private, repeatable checklist.
Sign in on the next page to save a private analysis.
Start analysisFAQ
Common questions about CVRX
Resolve the remaining questions before moving into the detailed workspaces.
Explore
Continue your research
Open the detailed valuation, financial, health, and management workspaces.
Continue the stock analysis
Jump to another research area for this company.